# CD8 Technology signs letter of intent for Tevogen Bio's cell therapy manufacturing facility

CD8 Technology Services LLC signed a letter of intent for a facility to support Tevogen Bio's cell therapy manufacturing, marking the first phase of up to $50 million commitment.

- Type: Contract
- Announced: 2025-04-30
- Where: Warren, New Jersey, United States
- Value: $50.0M
- Status: announced
- Products: cell therapy manufacturing facility
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CD8 Technology Services](https://endata.com/companies/84468.md) (supplier)
- [Tevogen Bio Holdings](https://endata.com/companies/84469.md) (customer)

## Sources

- [business.thepilotnews.com](https://business.thepilotnews.com/thepilotnews/article/gnwcq-2025-4-30-cd8-technology-signs-letter-of-intent-for-tevogen-bios-in-house-manufacturing-facility-marking-first-phase-of-up-to-50-million-commitment), 2025-04-30: "In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest value on business discipline."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.